Children in the world's poorest countries to get free insulin
- Details
- Category: Novo Nordisk
Novo Nordisk has announced that it will provide diabetes care, including free insulin, to 10,000 children in some of the world's poorest countries. The five-year programme, called 'Changing the Future for Children with Diabetes', will begin in 2009 with an initial roll-out in Uganda, Tanzania, Guinea-Conakry and the Democratic Republic of Congo.
Roche signs definitive agreement to acquire Memory Pharmaceuticals
- Details
- Category: Roche
Roche and Memory Pharmaceuticals have announced that the two companies have signed a definitive merger agreement for Roche to fully acquire Memory in an all-cash transaction at a price of approximately USD 50 million.
Pfizer's Novel HIV/AIDS Treatment SELZENTRY™
- Details
- Category: Pfizer
The U.S. Food and Drug Administration (FDA) has granted SELZENTRY™ (maraviroc) full (traditional) approval for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination with other antiretrovirals. SELZENTRY was originally granted accelerated conditional approval in August 2007 based on 24-week data from pivotal Phase 3 studies. SELZENTRY now becomes the latest fully approved treatment for HIV.
AstraZeneca Settles US Pulmicort Respules Patent Litigation with Teva
- Details
- Category: AstraZeneca
AstraZeneca has entered into a settlement agreement in its Pulmicort Respules patent infringement litigation against Ivax Pharmaceuticals, Inc., a wholly owned subsidiary of Teva Pharmaceuticals USA. The agreement settles the patent infringement litigation filed by AstraZeneca following Teva's submission to the United States Food & Drug Administration of an Abbreviated New Drug Application for a generic version of Pulmicort Respules.
Sandoz receives positive EU opinion for biosimilar filgrastim
- Details
- Category: Novartis
Sandoz has received a positive opinion from European regulators for its third biosimilar medicine, filgrastim, marking another important milestone in its efforts to bring affordable high-quality biopharmaceuticals to patients worldwide.
Johnson & Johnson Announces Definitive Agreement to Acquire Omrix
- Details
- Category: Financial
Johnson & Johnson (NYSE: JNJ) and Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI), a fully integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, have announced a definitive agreement whereby Omrix will be acquired for approximately $438 million in a cash tender offer.
GSK and Neptunus form joint venture for the co-development of flu vaccines
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) has signed an exclusive Cooperation Agreement with Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. (NIBT) as a preliminary step in forming a Joint Venture (JV) between the two companies. The agreement outlines the proposed terms for establishing a JV company, which will seek to co-develop seasonal influenza vaccines and pre-pandemic/pandemic influenza vaccines, firstly targeting against strains of the virus specific to China, Hong Kong and Macau.
More Pharma News ...
- AstraZeneca to divest Nordic over-the-counter portfolio
- Pfizer withdraws its application to change the marketing authorisation for Viagra
- AstraZeneca granted Temporary Restraining Order in PULMICORT RESPULES patent litigation
- Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of All Infants
- Pfizer Launches Global Regenerative Medicine Research Unit
- SEROQUEL XR and SEROQUEL Approved in Europe for New Indications
- Tarceva brings new hope to patients with advanced non-small cell lung cancer